Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 26, Issue 3, Pages 397-410Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2015.12.039
Keywords
5-HT1A; Depression; Review
Funding
- National Institutes of Health [R01MH074813, R01MH090276, K01MH091354]
- Clinical and Translational Science Award (CTSA) from Columbia University
- American Foundation for the Prevention of Suicide (AFSP)
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
Ask authors/readers for more resources
Major Depressive Disorder (MDD) is a highly prevalent psychiatric diagnosis that is associated with a high degree of morbidity and mortality. This debilitating disorder is currently one of the leading causes of disability nationwide and is predicted to be the leading cause of disease burden by the year 2030. A large body of previous research has theorized that serotonergic dysfunction, specifically of the serotonin (5-HT) 1A receptor, plays a key role in the development of MDD. The purpose of this review is to describe the evolution of our current understanding of the serotonin 1A (5-HT1A) receptor and its role in the pathophysiology MDD through the discussion of animal, post-mortem, positron emission tomography (PET), pharmacologic and genetic studies. (C) 2016 Elsevier B.V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available